The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Oxaliplatin: A Review in the Era of Molecularly Targeted Therapy
Open accessAbstract
Objective: To review preclinical and clinical data for oxaliplatin in the current context of molecularly targeted therapy. Methods of Study Selection: We searched the PubMed and PubChem databases by combining the search terms “oxaliplatin” or “platinum” or both, with “clinical trials,” “pharmacokinetics,” and “pharmacodynamics”. Data Extraction and Synthesis: Oxaliplatin has a complicated pharmacokinetic profile, with activity against digestive cancers in particular. It has several mechanisms of action, but cancer cells can develop resistance. Real or potential synergism has been observed when oxaliplatin is combined with other cytotoxic agents or molecularly targeted agents. Peripheral neuropathy is a prominent toxic effect. Conclusions: Oxaliplatin lends itself to further clinical research in combination with molecularly targeted therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Saltz, L. B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9930 · Cited by 2,955
Tournigand, C., André, T., Achille, E., Lledo, G., Flesh, M., Mery-Mignard, D., Quinaux, E., Couteau, C., Buyse, M., Ganem, G., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.113 · Cited by 2,915
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
Cunningham, D., Starling, N., Rao, S., Iveson, T., Nicolson, M., Coxon, F., Middleton, G., Daniel, F., Oates, J., & Norman, A. R. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa073149 · Cited by 2,285
Giantonio, B. J., Catalano, P. J., Meropol, N. J., O'Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., & Benson, A. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6305 · Cited by 2,279
André, T., Boni, C., Navarro, M., Tabernero, J., Hickish, T., Topham, C., Bonetti, A., Clingan, P., Bridgewater, J., Rivera, F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.6771 · Cited by 2,277
Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
Tol, J., Koopman, M., Cats, A., Rodenburg, C. J., Creemers, G. J. M., Schrama, J. G., Erdkamp, F. L. G., Vos, A. H., van Groeningen, C. J., Sinnige, H. A. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808268 · Cited by 1,341
Immunogenic death of colon cancer cells treated with oxaliplatin
Tesniere, A., Schlemmer, F., Boige, V, Kepp, O., Martins, I., Ghiringhelli, F., Aymeric, L., Michaud, M., Apetoh, L., Barault, L., et al. (2010) · Oncogene · doi:10.1038/onc.2009.356 · Cited by 1,173
Platinum Resistance: The Role of DNA Repair Pathways
Martin, L. P., Hamilton, T. C., & Schilder, R. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2238 · Cited by 751
Oxaliplatin: A review of preclinical and clinical studies
Raymond, E., Chaney, S. G., Taamma, A., & Cvitkovic, E. (1998) · Annals of Oncology · doi:10.1023/a:1008213732429 · Cited by 643
Inhibition of transcription by platinum antitumor compounds
Todd, R. C., & Lippard, S. J. (2009) · Metallomics · doi:10.1039/b907567d · Cited by 539
Cassidy, J., Tabernero, J., Twelves, C., Brunet, R., Butts, C., Conroy, T., Debraud, F., Figer, A., Grossmann, J., Sawada, N., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.069 · Cited by 525
Beuvink, I., Boulay, A., Fumagalli, S., Zilbermann, F., Ruetz, S., O’Reilly, T., Natt, F., Hall, J., Lane, H. A., & Thomas, G. (2005) · Cell · doi:10.1016/j.cell.2004.12.040 · Cited by 486
Clinical pharmacokinetics of oxaliplatin: a critical review.
Graham, M. A., Lockwood, G. F., Greenslade, D., Brienza, S., Bayssas, M., & Gamelin, E. (2000) · PubMed · Cited by 455
Machover, D., Diaz-Rubio, E., de Gramont, A., Schilf, A., Gastiaburu, J.-J., Brienza, S., Itzhaki, M., Metzger, G., N'Daw, D., Vignoud, J., et al. (1996) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a010489 · Cited by 434
Prevention of Oxaliplatin-Related Neurotoxicity by Calcium and Magnesium Infusions
Gamelin, L., Boisdron‐Celle, M., Delva, R., Guerin‐Meyer, V., Ifrah, N., Morel, A., & Gamelin, E. C. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0666 · Cited by 385
Grolleau, F., Gamelin, L., Boisdron-Celle, M., Lapied, B., Pelhate, M., & Gamelin, E. (2001) · Journal of Neurophysiology · doi:10.1152/jn.2001.85.5.2293 · Cited by 344
Phase I study of oxaliplatin in patients with advanced cancer
Extra, J. M., Espie, M., Calvo, F., Ferme, C., Mignot, L., & Marty, M. (1990) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00684890 · Cited by 343
Lévi, F., Misset, J.-L., Brienza, S., Adam, R., Metzger, G., Itzakhi, M., Caussanel, J.-P., Kunstlinger, F., Lecouturier, S., Descorps-Declère, A., et al. (1992) · Cancer · doi:10.1002/1097-0142(19920215)69:4<893::aid-cncr2820690410>3.0.co;2-x · Cited by 343
A review on oxaliplatin-induced peripheral nerve damage
Argyriou, A. A., Polychronopoulos, P., Iconomou, G., Chroni, E., & Kalofonos, H. P. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.01.003 · Cited by 330
Oxaliplatin-Induced Damage of Cellular DNA
Woynarowski, J. M., Faivre, S., Herzig, M. C. S., Arnett, B., Chapman, W. G., Trevino, A. V., Raymond, E., Chaney, S. G., Vaisman, A., Varchenko, M., et al. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12463-7 · Cited by 310
Maindrault-Goebel, F., Louvet, C., André, T., Carola, E., Lotz, J. P., Molitor, J. L., Garcia, M. L., Gilles-Amar, V, Izrael, V, Krulik, M., et al. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00149-5 · Cited by 290
Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat
Cavaletti, G., Tredici, G., Petruccioli, M. G., Dondè, E., Tredici, P., Marmiroli, P., Minoia, C., Ronchi, A., Bayssas, M., & Griffon Etienne, G. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00300-8 · Cited by 281
Reardon, J. T., Vaisman, A., Chaney, S. G., & Sancar, A. (1999) · PubMed · Cited by 281
Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells
Arango, D., Wilson, A. J., Shi, Q., Corner, G. A., Arañes, M. J., Nicholas, C., Lesser, M., Mariadason, J. M., & Augenlicht, L. H. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602215 · Cited by 274
Saltz, L. B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02760 · Cited by 239
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Bordonaba, F. A. M. (2009) · Yearbook of Pathology and Laboratory Medicine · doi:10.1016/s1077-9108(08)79091-1 · Cited by 230
Díaz-Rubio, E., Sastre, J., Zaniboni, A., Labianca, R., Cortés-Funes, H., de Braud, F., Boni, C., Benavides, M., Dallavalle, G., & Homerin, M. (1998) · Annals of Oncology · doi:10.1023/a:1008200825886 · Cited by 228
Culy, C. R., Clemett, D., & Wiseman, L. R. (2000) · Drugs · doi:10.2165/00003495-200060040-00005 · Cited by 217
DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells
Faivre, S., Chan, D., Salinas, R., Woynarowska, B., & Woynarowski, J. M. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(03)00260-0 · Cited by 211
Park, S., Krishnan, A., Lin, C., Goldstein, D., Friedlander, M., & Kiernan, M. (2008) · Current Medicinal Chemistry · doi:10.2174/092986708786848569 · Cited by 208
Cellular and molecular aspects of drugs of the future: oxaliplatin
Di Francesco, A. M., Ruggiero, A., & Riccardi, R. (2002) · Cellular and Molecular Life Sciences · doi:10.1007/pl00012514 · Cited by 207
Tournigand, C., André, T., Achille, E., Lledo, G., Flesh, M., Mery-Mignard, D., Quinaux, E., Couteau, C., Buyse, M., Ganem, G., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02774 · Cited by 187
FDA Drug Approval Summaries: Oxaliplatin
Ibrahim, A., Hirschfeld, S., Cohen, M. H., Griebel, D. J., Williams, G. A., & Pazdur, R. (2004) · The Oncologist · doi:10.1634/theoncologist.9-1-8 · Cited by 180
Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy
KWEEKEL, D., GELDERBLOM, H., & GUCHELAAR, H. (2005) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2004.12.006 · Cited by 179
Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines
Arnould, S., Hennebelle, I., Canal, P., Bugat, R., & Guichard, S. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00411-2 · Cited by 168
Giantonio, B. J., Catalano, P. J., Meropol, N. J., O'Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., & Benson, A. B. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02761 · Cited by 162
Wolmark, N., Yothers, G., O'Connell, M. J., Sharif, S., Atkins, J., Seay, T. E., Feherenbacher, L., O’Reilly, S., & Allegra, C. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.lba4 · Cited by 132
Pharmacokinetics of Oxaliplatin in Humans
Ehrsson, H., Wallin, I., & Yachnin, J. (2002) · Medical Oncology · doi:10.1385/mo:19:4:261 · Cited by 120
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
Bölke, E., Peiper, M., & Budach, W. (2008) · New England Journal of Medicine · doi:10.1056/nejmc080178 · Cited by 113
Long-term platinum retention after treatment with cisplatin and oxaliplatin
Brouwers, E. E. M., Huitema, A. D. R., Beijnen, J. H., & Schellens, J. H. M. (2008) · BMC Clinical Pharmacology · doi:10.1186/1472-6904-8-7 · Cited by 107
A phase I trial of trans-1-diaminocyclohexane oxalato-platinum (l-OHP).
Mathé, G., Kidani, Y., Triana, K., Brienza, S., Ribaud, P., Goldschmidt, E., Ecstein, E., Despax, R., Musset, M., & Misset, J. L. (1986) · PubMed · Cited by 92
Oettle, H., Pelzer, U., Stieler, J., Hilbig, A., Roll, L., Schwaner, I., Adler, M., Detken, S., Dörken, B., & Riess, H. B. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.4031 · Cited by 91
Douillard, J., Siena, S., Cassidy, J., Tabernero, J. M., Burkes, R. L., Barugel, M. E., Humblet, Y., Cunningham, D., Wolf, M., & Gansert, J. L. (2009) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(09)72039-7 · Cited by 89
Prewett, M. C., Deevi, D. S., Bassi, R., Fan, F., Ellis, L. M., Hicklin, D. J., & Tonra, J. R. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1768 · Cited by 52
Oxaliplatin-Related Acute Myelogenous Leukemia
Carneiro, B. A., Kaminer, L. S., Eldibany, M., Sreekantaiah, C., Kaul, K. L., & Locker, G. Y. (2006) · The Oncologist · doi:10.1634/theoncologist.11-3-261 · Cited by 21
Cohen, S. J., Engstrom, P. F., Lewis, N. L., Langer, C. J., McLaughlin, S. B., Beard, M., Weiner, L. M., & Meropol, N. J. (2008) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e31805c142f · Cited by 12
Cited by
Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy
Starobova, H., & Vetter, I. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00174 · Cited by 648
Zheng, M., Liu, S., Li, J., Qu, D., Zhao, H., Guan, X., Hu, X., Xie, Z., Jing, X., & Sun, Z. (2014) · Advanced Materials · doi:10.1002/adma.201306192 · Cited by 588
Carbon quantum dots: recent progresses on synthesis, surface modification and applications
Farshbaf, M., Davaran, S., Rahimi, F., Annabi, N., Salehi, R., & Akbarzadeh, A. (2018) · Artificial Cells, Nanomedicine, and Biotechnology · doi:10.1080/21691401.2017.1377725 · Cited by 265
Makker, P. G. S., Duffy, S. S., Lees, J. G., Perera, C. J., Tonkin, R. S., Butovsky, O., Park, S. B., Goldstein, D., & Moalem-Taylor, G. (2017) · PLOS ONE · doi:10.1371/journal.pone.0170814 · Cited by 254
Nam, G.-H., Kwon, M., Jung, H., Ko, E., Kim, S. A., Choi, Y., Song, S. J., Kim, S., Lee, Y., Kim, G. B., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002474 · Cited by 82
Metadata
- Authors
- Alcindor, T., & Beauger, N.
- Venue
- Current Oncology
- Publisher
- MDPI AG
- Published
- 2011-02-01
- Volume
- 18
- Issue
- 1
- Pages
- 18-25
- ISSN
- 1198-0052 (ISSN-L)
- 1718-7729
- OpenAlex
- W2098749704
- Cited by
- 432
- References
- 48
- FWCI
- 4.96
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.